RS67295B1 - Postupci za tretman hiperfenilalaninemje - Google Patents

Postupci za tretman hiperfenilalaninemje

Info

Publication number
RS67295B1
RS67295B1 RS20250917A RSP20250917A RS67295B1 RS 67295 B1 RS67295 B1 RS 67295B1 RS 20250917 A RS20250917 A RS 20250917A RS P20250917 A RSP20250917 A RS P20250917A RS 67295 B1 RS67295 B1 RS 67295B1
Authority
RS
Serbia
Prior art keywords
day
sepiapterin
patient
pharmaceutically acceptable
per liter
Prior art date
Application number
RS20250917A
Other languages
English (en)
Serbian (sr)
Inventor
Niel Smith
Original Assignee
Ptc Therapeutics Mp Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Mp Inc filed Critical Ptc Therapeutics Mp Inc
Publication of RS67295B1 publication Critical patent/RS67295B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
RS20250917A 2019-09-25 2020-09-25 Postupci za tretman hiperfenilalaninemje RS67295B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962905720P 2019-09-25 2019-09-25
EP20789788.5A EP4034122B1 (en) 2019-09-25 2020-09-25 Methods for treating hyperphenylalaninemia
PCT/US2020/052871 WO2021062264A1 (en) 2019-09-25 2020-09-25 Methods for treating hyperphenylalaninemia

Publications (1)

Publication Number Publication Date
RS67295B1 true RS67295B1 (sr) 2025-11-28

Family

ID=72827023

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20250917A RS67295B1 (sr) 2019-09-25 2020-09-25 Postupci za tretman hiperfenilalaninemje

Country Status (22)

Country Link
US (1) US20220362249A1 (https=)
EP (1) EP4034122B1 (https=)
JP (2) JP7661315B2 (https=)
KR (1) KR20220070477A (https=)
CN (1) CN114650825A (https=)
BR (1) BR112022003719A2 (https=)
CA (1) CA3150003A1 (https=)
DK (1) DK4034122T3 (https=)
ES (1) ES3041002T3 (https=)
FI (1) FI4034122T3 (https=)
HR (1) HRP20251268T1 (https=)
HU (1) HUE073483T2 (https=)
IL (1) IL291565B1 (https=)
JO (1) JOP20220042A1 (https=)
LT (1) LT4034122T (https=)
MX (1) MX2022003585A (https=)
PL (1) PL4034122T3 (https=)
PT (1) PT4034122T (https=)
RS (1) RS67295B1 (https=)
SI (1) SI4034122T1 (https=)
SM (1) SMT202500493T1 (https=)
WO (1) WO2021062264A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA46973A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Polymorphes de sépiaptérine et leurs sels
MA46972A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Forme polymorphe de sépiaptérine
JP7811085B2 (ja) 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
FI3801536T3 (fi) 2018-05-30 2024-08-29 Ptc Therapeutics Mp Inc Sepiapteriinin antaminen ilman ruokaa käytettäväksi menetelmässä sepiapteriinin plasma-altistuksen lisäämiseksi
EP3801534B1 (en) * 2018-05-30 2026-02-18 PTC Therapeutics MP, Inc. Treatment of phenylketonuria with sepiapterin

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
ES2586945T3 (es) * 2014-03-31 2016-10-19 Vasopharm Gmbh Composiciones farmacéuticas sólidas que comprenden derivados de biopterina y usos de dichas composiciones
MA46973A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Polymorphes de sépiaptérine et leurs sels
MA46972A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Forme polymorphe de sépiaptérine
JP7811085B2 (ja) * 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
AU2019277372B2 (en) 2018-05-30 2024-12-19 Ptc Therapeutics Mp, Inc. Pharmaceutically acceptable salts of sepiapterin

Also Published As

Publication number Publication date
SMT202500493T1 (it) 2026-01-12
SI4034122T1 (sl) 2025-12-31
IL291565B1 (en) 2026-04-01
AU2020353676A1 (en) 2022-04-14
HUE073483T2 (hu) 2026-01-28
FI4034122T3 (fi) 2025-10-08
IL291565A (en) 2022-05-01
CA3150003A1 (en) 2021-04-01
DK4034122T3 (da) 2025-09-15
LT4034122T (lt) 2025-11-10
JP2025111476A (ja) 2025-07-30
JP2022549834A (ja) 2022-11-29
JOP20220042A1 (ar) 2023-01-30
HRP20251268T1 (hr) 2025-12-05
PT4034122T (pt) 2025-09-18
WO2021062264A1 (en) 2021-04-01
MX2022003585A (es) 2022-04-19
CN114650825A (zh) 2022-06-21
EP4034122A1 (en) 2022-08-03
ES3041002T3 (en) 2025-11-06
JP7661315B2 (ja) 2025-04-14
US20220362249A1 (en) 2022-11-17
EP4034122B1 (en) 2025-08-13
BR112022003719A2 (pt) 2022-05-31
KR20220070477A (ko) 2022-05-31
PL4034122T3 (pl) 2026-01-26

Similar Documents

Publication Publication Date Title
EP4034122B1 (en) Methods for treating hyperphenylalaninemia
JP7811085B2 (ja) セピアプテリンを含む医薬組成物及びその使用
EP3801536B1 (en) Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure
EP3801534B1 (en) Treatment of phenylketonuria with sepiapterin
US10888571B2 (en) Method and composition for increasing muscle protein synthesis and/or functional strength in mammals
AU2024274445A1 (en) Sleep-improving compositions and methods of use
AU2020353676B2 (en) Methods for treating hyperphenylalaninemia
HK40081378A (en) Methods for treating hyperphenylalaninemia
HK40081378B (en) Methods for treating hyperphenylalaninemia
EA047419B1 (ru) Способы лечения гиперфенилаланинемии
EA052959B1 (ru) Способы лечения гиперфенилаланинемии
CA3165636A1 (en) Methods for treating parkinson's disease with sepiapterin
CA3207811A1 (en) Methods for treating glioblastomas with sepiapterin
HK40051961B (en) Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure
HK40051961A (en) Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure
WO2022173823A1 (en) Methods for treating covid-19 with sepiapterin